High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias

Hong Li, Paul N Black, Aalap Chokshi, Angel Sandoval-Alvarez, Ravi Vatsyayan, Whitney Sealls, Concetta C DiRusso

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Fatty acids are implicated in the development of dyslipidemias, leading to type 2 diabetes and cardiovascular disease. We used a standardized small compound library to screen humanized yeast to identify compounds that inhibit fatty acid transport protein (FATP)-mediated fatty acid uptake into cells. This screening procedure used live yeast cells expressing human FATP2 to identify small compounds that reduced the import of a fluorescent fatty acid analog, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C 1-BODIPY-C12). The library used consisted of 2,080 compounds with known biological activities. Of these, ∼1.8% reduced cell-associated C1-BODIPY-C12 fluorescence and were selected as potential inhibitors of human FATP2-mediated fatty acid uptake. Based on secondary screens, 28 compounds were selected as potential fatty acid uptake inhibitors. Some compounds fell into four groups with similar structural features. The largest group was structurally related to a family of tricyclic, phenothiazine-derived drugs used to treat schizophrenia and related psychiatric disorders, which are also known to cause metabolic side effects, including hypertriglyceridemia. Potential hit compounds were studied for specificity of interaction with human FATP and efficacy in human Caco-2 cells. This study validates this screening system as useful to assess the impact of drugs in preclinical screening for fatty acid uptake.

Original languageEnglish (US)
Pages (from-to)230-244
Number of pages15
JournalJournal of Lipid Research
Volume49
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Dyslipidemias
Yeast
Antipsychotic Agents
Screening
Fatty Acids
Yeasts
Throughput
Fatty Acid Transport Proteins
lauric acid
Libraries
Caco-2 Cells
Hypertriglyceridemia
Medical problems
Bioactivity
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Psychiatry
Schizophrenia
Cardiovascular Diseases
Fluorescence

Keywords

  • 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s- indacene-3-dodecanoic acid
  • Caco-2
  • Fatty acid transport protein
  • Yeast

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias. / Li, Hong; Black, Paul N; Chokshi, Aalap; Sandoval-Alvarez, Angel; Vatsyayan, Ravi; Sealls, Whitney; DiRusso, Concetta C.

In: Journal of Lipid Research, Vol. 49, No. 1, 01.01.2008, p. 230-244.

Research output: Contribution to journalArticle

@article{5a0752e7a4e44d58b85561dfb535bbce,
title = "High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias",
abstract = "Fatty acids are implicated in the development of dyslipidemias, leading to type 2 diabetes and cardiovascular disease. We used a standardized small compound library to screen humanized yeast to identify compounds that inhibit fatty acid transport protein (FATP)-mediated fatty acid uptake into cells. This screening procedure used live yeast cells expressing human FATP2 to identify small compounds that reduced the import of a fluorescent fatty acid analog, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C 1-BODIPY-C12). The library used consisted of 2,080 compounds with known biological activities. Of these, ∼1.8{\%} reduced cell-associated C1-BODIPY-C12 fluorescence and were selected as potential inhibitors of human FATP2-mediated fatty acid uptake. Based on secondary screens, 28 compounds were selected as potential fatty acid uptake inhibitors. Some compounds fell into four groups with similar structural features. The largest group was structurally related to a family of tricyclic, phenothiazine-derived drugs used to treat schizophrenia and related psychiatric disorders, which are also known to cause metabolic side effects, including hypertriglyceridemia. Potential hit compounds were studied for specificity of interaction with human FATP and efficacy in human Caco-2 cells. This study validates this screening system as useful to assess the impact of drugs in preclinical screening for fatty acid uptake.",
keywords = "4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s- indacene-3-dodecanoic acid, Caco-2, Fatty acid transport protein, Yeast",
author = "Hong Li and Black, {Paul N} and Aalap Chokshi and Angel Sandoval-Alvarez and Ravi Vatsyayan and Whitney Sealls and DiRusso, {Concetta C}",
year = "2008",
month = "1",
day = "1",
doi = "10.1194/jlr.D700015-JLR200",
language = "English (US)",
volume = "49",
pages = "230--244",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias

AU - Li, Hong

AU - Black, Paul N

AU - Chokshi, Aalap

AU - Sandoval-Alvarez, Angel

AU - Vatsyayan, Ravi

AU - Sealls, Whitney

AU - DiRusso, Concetta C

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Fatty acids are implicated in the development of dyslipidemias, leading to type 2 diabetes and cardiovascular disease. We used a standardized small compound library to screen humanized yeast to identify compounds that inhibit fatty acid transport protein (FATP)-mediated fatty acid uptake into cells. This screening procedure used live yeast cells expressing human FATP2 to identify small compounds that reduced the import of a fluorescent fatty acid analog, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C 1-BODIPY-C12). The library used consisted of 2,080 compounds with known biological activities. Of these, ∼1.8% reduced cell-associated C1-BODIPY-C12 fluorescence and were selected as potential inhibitors of human FATP2-mediated fatty acid uptake. Based on secondary screens, 28 compounds were selected as potential fatty acid uptake inhibitors. Some compounds fell into four groups with similar structural features. The largest group was structurally related to a family of tricyclic, phenothiazine-derived drugs used to treat schizophrenia and related psychiatric disorders, which are also known to cause metabolic side effects, including hypertriglyceridemia. Potential hit compounds were studied for specificity of interaction with human FATP and efficacy in human Caco-2 cells. This study validates this screening system as useful to assess the impact of drugs in preclinical screening for fatty acid uptake.

AB - Fatty acids are implicated in the development of dyslipidemias, leading to type 2 diabetes and cardiovascular disease. We used a standardized small compound library to screen humanized yeast to identify compounds that inhibit fatty acid transport protein (FATP)-mediated fatty acid uptake into cells. This screening procedure used live yeast cells expressing human FATP2 to identify small compounds that reduced the import of a fluorescent fatty acid analog, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C 1-BODIPY-C12). The library used consisted of 2,080 compounds with known biological activities. Of these, ∼1.8% reduced cell-associated C1-BODIPY-C12 fluorescence and were selected as potential inhibitors of human FATP2-mediated fatty acid uptake. Based on secondary screens, 28 compounds were selected as potential fatty acid uptake inhibitors. Some compounds fell into four groups with similar structural features. The largest group was structurally related to a family of tricyclic, phenothiazine-derived drugs used to treat schizophrenia and related psychiatric disorders, which are also known to cause metabolic side effects, including hypertriglyceridemia. Potential hit compounds were studied for specificity of interaction with human FATP and efficacy in human Caco-2 cells. This study validates this screening system as useful to assess the impact of drugs in preclinical screening for fatty acid uptake.

KW - 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s- indacene-3-dodecanoic acid

KW - Caco-2

KW - Fatty acid transport protein

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=38049141096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049141096&partnerID=8YFLogxK

U2 - 10.1194/jlr.D700015-JLR200

DO - 10.1194/jlr.D700015-JLR200

M3 - Article

VL - 49

SP - 230

EP - 244

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 1

ER -